90 related articles for article (PubMed ID: 2657866)
21. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.
Vyas KP; Halpin RA; Geer LA; Ellis JD; Liu L; Cheng H; Chavez-Eng C; Matuszewski BK; Varga SL; Guiblin AR; Rogers JD
Drug Metab Dispos; 2000 Jan; 28(1):89-95. PubMed ID: 10611145
[TBL] [Abstract][Full Text] [Related]
22. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
23. Disposition of 3H-enisoprost, a gastric antisecretory prostaglandin, in healthy humans.
Allan LM; Hawkins AJ; Vose CW; Firth J; Brownsill RD; Steiner JA
Xenobiotica; 1987 Oct; 17(10):1233-46. PubMed ID: 3424870
[TBL] [Abstract][Full Text] [Related]
24. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil.
Muirhead GJ; Rance DJ; Walker DK; Wastall P
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):13S-20S. PubMed ID: 11879255
[TBL] [Abstract][Full Text] [Related]
25. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.
Wade M; Baker FJ; Roscigno R; DellaMaestra W; Hunt TL; Lai AA
J Clin Pharmacol; 2004 Jan; 44(1):83-8. PubMed ID: 14681345
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects.
Nave R; Bethke TD; van Marle SP; Zech K
Clin Pharmacokinet; 2004; 43(7):479-86. PubMed ID: 15139796
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of NS-105, a novel cognition enhancer. 1st communication: absorption, metabolism and excretion in rats, dogs and monkeys after single administration of 14C-NS-105.
Mukai H; Sugimoto T; Ago M; Morino A
Arzneimittelforschung; 1999 Nov; 49(11):881-90. PubMed ID: 10604039
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of 3H-terguride in elderly volunteers.
Krause W; Kühne G; Seifert W
Arzneimittelforschung; 1991 Apr; 41(4):373-7. PubMed ID: 1859510
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and disposition of carvedilol in humans.
Neugebauer G; Akpan W; von Möllendorff E; Neubert P; Reiff K
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S85-8. PubMed ID: 2454375
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers.
Kramer WG; Nagabhushan N; Affrime MB; Perentesis GP; Symchowicz S; Patrick JE
J Clin Pharmacol; 1988 Jul; 28(7):644-8. PubMed ID: 3216030
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and biotransformation of the anxiolytic abecarnil in healthy volunteers.
Krause W; Duka T; Matthes H
Xenobiotica; 1991 Jun; 21(6):763-74. PubMed ID: 1683073
[TBL] [Abstract][Full Text] [Related]
32. Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.
van Hecken AM; Tjandramaga TB; Mullie A; Verbesselt R; de Schepper PJ
Br J Clin Pharmacol; 1982 Aug; 14(2):195-200. PubMed ID: 6125204
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of fluconazole in normal volunteers.
Ripa S; Ferrante L; Prenna M
Chemotherapy; 1993; 39(1):6-12. PubMed ID: 8444063
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and metabolism of [
Mancel V; Mathy FX; Boulanger P; English S; Croft M; Kenney C; Knott T; Stockis A; Bani M
Xenobiotica; 2017 Aug; 47(8):705-718. PubMed ID: 27489076
[TBL] [Abstract][Full Text] [Related]
35. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of hydroxy-3(S)-dihydroquinidine in healthy volunteers after intravenous and oral administration.
Jaillon P; Poirier JM; Lecocq B; Jarreau C; Pays M; Richard MO; Cheymol G
Eur J Drug Metab Pharmacokinet; 1986; 11(3):233-8. PubMed ID: 3816879
[TBL] [Abstract][Full Text] [Related]
37. Functional pharmacology of human prostanoid EP2 and EP4 receptors.
Wilson RJ; Rhodes SA; Wood RL; Shield VJ; Noel LS; Gray DW; Giles H
Eur J Pharmacol; 2004 Oct; 501(1-3):49-58. PubMed ID: 15464062
[TBL] [Abstract][Full Text] [Related]
38. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
39. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans.
Neugebauer G; Wittenbrink-Dix AM; Woelke-Seidl E; Kaufmann B; Ponton T; Dahmen W; Mosberg H; Nieder N; Besenfelder E
Arzneimittelforschung; 1989 Oct; 39(10A):1336-9. PubMed ID: 2576358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]